#United States #Detroit #Karmanos Cancer Institute #TheraBionic P1 #U CAN-CER VIVE

U CAN-CER VIVE Foundation Supports Karmanos Cancer Institute

The fight against cancer has received a significant boost thanks to the U CAN-CER VIVE Foundation, which has granted $459,010 to the Barbara Ann Karmanos Cancer Institute. This funding is dedicated to expanding clinical trial research into innovative cancer treatments using radiofrequency electromagnetic fields. This initiative aims to enhance treatment options for various cancer types, particularly breast, colorectal, and pancreatic cancers.

The presentation of the donation took place in March, with representatives from the U CAN-CER VIVE Foundation, established by Ryan and Kelley LaFontaine, personally delivering the check. Their ongoing commitment to cancer research has positioned them as pivotal supporters of scientific advancements in Michigan. According to Dr. Anthony Shields, a prominent medical oncologist at Karmanos, this funding allows researchers to push the envelope on what’s possible in cancer treatment.

The Role of the TheraBionic P1 Device

One of the cornerstones of this research is the TheraBionic P1 device, which gained FDA approval to treat advanced hepatocellular carcinoma (HCC), the most prevalent form of liver cancer. Over two decades of extensive research have indicated that this device can reduce tumor sizes, inhibit further growth of cancer cells, and enhance overall survival rates for patients.

Clinical trial participants have reported an absence of severe side effects typically linked to traditional cancer treatments, such as loss of appetite or gastrointestinal distress. Remarkably, one patient experienced a significant extension in life expectancy, living nearly six years post-recurrence of HCC while utilizing the device.

Innovative Treatment Approach

The TheraBionic P1 operates by emitting low levels of 27.12 MHz radiofrequency electromagnetic fields, which are modulated at tumor-specific frequencies. This innovative approach allows patients to receive treatment in the comfort of their homes. By placing a spoon-shaped antenna on their tongue, patients engage in three hourly sessions daily where these frequencies target and communicate directly with tumor cells, halting their growth while sparing healthy tissues. It has been designed to be substantially safer, emitting lower frequency levels than those of cellular phones.

Dr. Boris Pasche, co-inventor of the device and current president and CEO of Karmanos, explains that the research team has discovered that various tumors respond to distinct frequencies. This ground-breaking methodology underscores the promise of the TheraBionic P1 in addressing a spectrum of cancers beyond liver cancer, including breast, pancreatic, and colorectal malignancies.

Looking to the Future

Anticipated trials supported by the U CAN-CER VIVE grant are scheduled to unfold in 2025, allowing clinical researchers to further explore treatment avenues for metastatic adenocarcinoma of the pancreas among other cancers. Presently, Karmanos is actively recruiting patients for these clinical trials, reflecting a proactive approach in deploying this novel therapy.

Kelley LaFontaine, co-founder of the U CAN-CER VIVE Foundation, shares their mission is not just about funding but also about fostering new horizons in cancer care. The commitment shown through this grant resonates deeply with every family affected by cancer, highlighting the transformative potential of medical research. As they support Karmanos' endeavors, they reaffirm their dedication to empowering researchers and offering renewed hope to patients denoted as being in the fight of their lives.

For further details on the clinical trials available through Karmanos Cancer Institute, including a comprehensive overview of ongoing research, interested parties can visit Karmanos.org.

About Karmanos Cancer Institute

The Barbara Ann Karmanos Cancer Institute stands as a beacon of excellence in cancer care, research, and education, backed by over 75 years of experience. Located in downtown Detroit, Karmanos is recognized as one of the foremost comprehensive cancer centers in the United States. As part of McLaren Health Care, it plays a vital role in advancing scientific knowledge and improving patient outcomes across Michigan and beyond.

With the commitment from both the U CAN-CER VIVE Foundation and Karmanos, the partnership anticipates ushering in new treatment frontiers to foster a brighter future in cancer therapy.